Companies · Other Health Care

Nymbl Science, Inc.

Denver · Other Health Care

Diligence memoA one-page analyst read on Nymbl Science, Inc. — recommendation, valuation, rhythm, risks.
$15.8M
Total raised · real
4
Rounds
0.1×
Latest step-up
Top 20%
Sector rank · raised
Series A
Latest stage · inferred · Fri Aug 29 2025 00:00:00 GMT+0000 (Coordinated Universal Time)

Nymbl Science, Inc. looks under-valued against its niche peers and is active on financing cadence.

Synthesized from the figures below est. — every claim rests on a number shown on this page. Valuation uses the health care sector profile.

Analyst read est. — computed against this company's niche peers in the same era. Inputs shown; not a quoted figure.

Under-valued
  • Modeled value is 0.19× the median modeled value of Series A Other Health Care companies in 2025–2027 (83 peers) — value vs value, same stage and era.
Active
  • Last raise 10 mo ago; this sector typically re-raises about every 14 months.
  • Raising on or ahead of the sector's normal rhythm.
Leadership

No named principal in this company's public records yet — see all operators below.

Explore how these operators interlock with other companies in the operator network.

Where it sits in Other Health Care

Nymbl Science, Inc. is one of 5376 Other Health Care companies tracked from Denver. By capital raised it ranks in the upper tier (ahead of 81% of sector peers), and in the long tail by modeled valuation est..

Ranking is computed against this company's own sector cohort — reported capital is fact; valuation tiers are modeled.

As reported in public records reported — not modeled.

US
Jurisdiction
Rule 506(b)
Reg D exemption
30
Investors (latest)
2025-08-29
First sale
Amount raised vs valuation, by round

Solid bars are reported offering amounts reported; hatched bars are the modeled post-money valuation est. — both on one shared scale so you can read raise-vs-worth at each round directly. Use the toggles to overlay data labels and the niche-peer / market average value lines.

Amount raised · realModeled valuation · estCumulative funded · real
$0$25M$50M$75M$100MSeed · 2019-06-27 Raised $2.3M (real) Modeled valuation $58M (est)$2.3M$58MSeed2019Seed · 2019-06-27 Raised $2.0M (real) Modeled valuation $49M (est)$2.0M$49MSeed2019Seed · 2020-09-24 Raised $3.7M (real) Modeled valuation $83M (est)$3.7M$83MSeed2020Series A · 2022-10-17 Raised $8.8M (real) Modeled valuation $78M (est)$8.8M$78MSeries A2022Series A · 2025-08-29 Raised $984K (real) Modeled valuation $3.1M (est)$984K$3.1MSeries A2025+$2.0M+$3.7M+$8.8M+$984KCumulative $18M

The line shows cumulative reported funding over the period; + labels show new capital added between points when there is room. Toggle on-bar figures, plus the niche-peer and market averages, to read this company against its cohort. Benchmarks are modeled medians.

Financing ladder & sequence gaps
Seed$2.3M · 2019
Seed extension$2.0M · 2019
Seed extension$3.7M · 2020
Series A$8.8M · 2022
Series A extension$984K · 2025

Stages are modeled from round size (public records carry no series label). No record for: Pre-Seed — the company may have raised it under a different exemption, merged it into an adjacent record, or skipped it. Sequence completeness: 67%.

Modeled valuation trajectory
$3.1M
Base estimate est.
$1.3M
Conservative case
$5.2M
Upside case
$4.5M
Modeled post-money

Round size and date are reported; the stage label is inferred from round size (latest is Series Aa $4.0M–$15M round). Valuation is modeled from stage benchmarks scaled by the health care sector profile. Directional, not a quoted figure.

Seed · modeled $57.6M · 2019-06-272019Seed · modeled $48.8M · 2019-06-27Seed · modeled $83.4M · 2020-09-24Series A · modeled $77.6M · 2022-10-17Series A · modeled $3.1M · 2025-08-292025
Model inputs · modeled:benchmark-stage-stepup-v1
22%
Dilution assumption
Implied ownership sold in the financing.
52%
Survival probability
28% low · 71% high
1.43×/yr
Annual markup
1.80×/yr upside case
0.8 yr
Elapsed time used
0.8 yr actual, capped for stale marks
health care
Sector profile
Adjusts growth and survival by industry.
Financing rhythm
19 mo
Avg between rounds
$2.6M/yr
Capital velocity
7.0 yr
On record since
2019
First round
5
Rounds on file
How it compares to the market

Benchmarked against 5376 companies in Other Health Care. Each bar is a median (the middle company, not an average — outliers don't skew it). Two yardsticks: real money raised (reported on Form D) and modeled value (our estimate est.). These are whole-sector medians across all stages, except the per-stage row.

Total raised — vs sector median (real $, all stages) 6.5× above median
This company$15.8M
Sector median$2.4M
Latest round — vs other Series A rounds in sector (real $, this stage) 0.2× of median
This company$984K
Sector median$5.6M
Modeled value — vs sector median (estimate, all stages) 0.1× of median
This company$3.1M
Sector median$22.1M

Raised more than 81% of sector peers (real $). Modeled value above 14% of peers (estimate).

Niche peers — same stage & era

A tighter cohort than the sector chart above — only companies at the same stage (Series A) that last raised in the same ~3-year era, ranked by modeled value est. (not money raised). This is the exact set the analyst read compares against, so a like-for-like cohort is what makes "over/under-valued" meaningful. This company ranks #71 of 83.

This companyCohort peer
$1.0M$10.0M$100.0M$1.0M$10.0M$100.0MCapital raised (log)HelloJoy, Inc. · Series A Raised $26.3M · modeled $55.0M (est)Maui Imaging, Inc. · Series A Raised $29.9M · modeled $51.0M (est)Celltrio, Inc. · Series A Raised $15.0M · modeled $50.8M (est)Medmo, Inc. · Series A Raised $31.7M · modeled $44.7M (est)Vertical Orthopaedics, Inc. · Series A Raised $16.7M · modeled $44.0M (est)AbriCare, Inc. · Series A Raised $15.0M · modeled $39.1M (est)WP Stillwater, LLC · Series A Raised $14.3M · modeled $38.1M (est)Sylke, Inc. · Series A Raised $15.9M · modeled $37.6M (est)Iridex Corp · Series A Raised $10.0M · modeled $37.2M (est)2GHealth Inc. · Series A Raised $17.5M · modeled $35.6M (est)Okc Alf 4, Llc · Series A Raised $8.9M · modeled $34.5M (est)HC Jones, Inc. · Series A Raised $14.1M · modeled $33.4M (est)Nymbl Science, Inc. (this company) Raised $15.8M · modeled $3.1M (est)Nymbl Science, Inc.
CompanyStageRaised · realValue · estvs peer med.
HelloJoy, Inc.Series A$26.3M$55.0M3.37×
Maui Imaging, Inc.Series A$29.9M$51.0M3.12×
Celltrio, Inc.Series A$15.0M$50.8M3.11×
Medmo, Inc.Series A$31.7M$44.7M2.74×
Vertical Orthopaedics, Inc.Series A$16.7M$44.0M2.69×
AbriCare, Inc.Series A$15.0M$39.1M2.39×
WP Stillwater, LLCSeries A$14.3M$38.1M2.33×
Sylke, Inc.Series A$15.9M$37.6M2.30×
Iridex CorpSeries A$10.0M$37.2M2.28×
2GHealth Inc.Series A$17.5M$35.6M2.18×
Okc Alf 4, LlcSeries A$8.9M$34.5M2.11×
HC Jones, Inc.Series A$14.1M$33.4M2.04×
Nymbl Science, Inc. this companySeries A$15.8M$3.1M0.19×
Full financing history

Stage is inferred from round size est., not reported on the filing — a round's dollar size maps to a bucket: Pre-Seed <$1.0M · Seed $1.0M–$4.0M · Series A $4.0M–$15M · Series B $15M–$40M · Series C $40M–$100M · Series D+ $100M–$400M · Growth/Late >$400M.

StageAmount · realAnnouncedPost-money · estValue · estConf.
Seed$2.3M2019-06-27$11.6M$57.6M90%
Seed$2.0M2019-06-27$9.8M$48.8M90%
Seed$3.7M2020-09-24$18.6M$83.4M90%
Series A$8.8M2022-10-17$39.8M$77.6M90%
Series A$984K2025-08-29$4.5M$3.1M90%
What happened at each round

Step-up, pace versus the sector's normal cadence, and revenue/exemption moves — read straight from the reported round facts reported.

  1. Seed$2.3M2019-06-27
    • First recorded raise — entered as Seed.
    • 27 investors on this round.
  2. Seed$2.0M2019-06-27
    • Filed alongside the prior round (same month) — likely a tranche or amendment.
    • Round roughly the size of the prior one.
    • 22 investors on this round.
  3. Seed$3.7M2020-09-24
    • Raised 15 mo later, in step with the ~14 mo sector norm.
    • Round 1.9× larger than the prior — scaling up.
    • 22 investors on this round.
  4. Series A$8.8M2022-10-17
    • Raised again after 25 mo — slower than the ~14 mo sector norm.
    • Round 2.4× larger than the prior — scaling up.
    • 23 investors on this round.
  5. Series A$984K2025-08-29
    • Raised again after 34 mo — slower than the ~14 mo sector norm.
    • Round 8.9× smaller than the prior — bridge or down round.
    • 30 investors on this round.
Intelligence
2027 ~Q1
Modeled next raise · ~19mo cadence
$984K
Modeled next size est.range $984K$1.6M
0.1×
Last step-up
$2.6M/yr
Capital velocity

Predictive signals are modeled est. from this company's own cadence and step-up, plus sector benchmarks — directional, not advice. Peer set and a CSV export live in your analyst workspace.

Key people & operators

Officers, directors and promoters named in this company's public recordsreported — the people who run it (not its investors). "Also runs" counts come from name-matching across all records, so verify before acting.

PersonRoleAlso runsTied since
James Cook4 other2019-06
Rohit Seth4 other2022-10
Chris Saxman1 other2019-06
David Eichler1 other2022-10
Edward Likovich1 other2019-06
Ben Wire2025-08
Caroline Owen-Jones2020-09
Carol Owens Jones2019-06
Dr. Jean-Pierre Farcy2019-06
Meghan Oliver2020-09
Philip Linville2022-10
Thomas Virden2019-06
Registry & provenance

Nymbl Science, Inc. is an official record sourced from the U.S. Securities and Exchange Commission (SEC). U.S. data is aggregated from SEC Form D filings.

United States
Country of record
US
Jurisdiction
1781552
SEC CIK
Similar companies

Nearest neighbours across the whole database — matched on sector, stage and capital scale, and on shared operators (officers or directors named at both companies in public filings). A discovery shortlist, not a valuation cohort — verify before acting, the same way modeled figures are directional.

CompanySectorStageRaised · realValue · estWhy similar
ChemoMouthpiece, LLCOther Health CareSeries A$15.9M$3.8Msame sector · same stage
RF Surgical Systems, IncOther Health CareSeries A$14.6M$2.4Msame sector · same stage
Omeza Holdings, Inc.Other Health CareSeries A$13.8M$3.7Msame sector · same stage
Family First, Inc.Other Health CareSeries A$18.6M$2.6Msame sector · same stage
Intrinsic Medical Imaging LLCOther Health CareSeries A$18.7M$2.5Msame sector · same stage
Assure Holdings Corp.Other Health CareSeries A$13.1M$2.6Msame sector · same stage
EpiEP, Inc.Other Health CareSeries A$20.5M$3.2Msame sector · same stage
Echo 360 Holdings, Inc.Other TechnologySeries A$17.8M$83.2Mnetwork1 shared operator · same stage
Semantically similar

Matched by meaning, not labels — a local language model reads each company's name, sector and description and ranks the closest in that learned space. This catches look-alikes that cross sector boundaries; the structured list above explains its matches, this one trusts the text. Directional, like every modeled signal here.

CompanySectorStageValue · estMatch
Xymogen, Inc.Other Health CareSeed$12.3M83%
TMRW Life Sciences, Inc.Other Health CareSeries D+$284.0M83%
Colorescience IncOther Health CareSeries B$66.5M82%
Ocular Science, Inc.Other Health CarePre-Seed$5.4M82%
Element Science, Inc.Other Health CareSeries C$1.2B82%
GeniPhys, Inc.Other Health CareSeries A$8.2M82%
Mindsciences, Inc.Other Health CareSeed$60.5M82%
NY Medicinal Research & Caring, LLCOther Health CareSeries A$178.0M82%
Frequently asked
How much funding has Nymbl Science, Inc. raised?
Nymbl Science, Inc. has raised approximately $15.8M in disclosed capital across 4 recorded financing rounds, aggregated from public filings.
What is Nymbl Science, Inc.'s estimated valuation?
Provath's modeled valuation for Nymbl Science, Inc. is approximately $3.1M (modeled range $1.3M–$5.2M). This is an algorithmic estimate derived from round sizes and same-niche peers — not a quoted or reported figure.
What funding stage is Nymbl Science, Inc. at?
Nymbl Science, Inc.'s latest modeled financing stage is Series A. Its most recent recorded round closed around Fri Aug 29.
What does Nymbl Science, Inc. do and where is it based?
Nymbl Science, Inc. operates in the Other Health Care sector, based in Denver.
Explore related

See where Nymbl Science, Inc. sits in the wider market — its sector, location and stage cohorts, each with their own leaderboards and capital-flow timelines.

Is this your company?

If you work at Nymbl Science, Inc., claim this profile or suggest a correction. We aggregate from public filings, so help us keep your description, website and links accurate.

Is this your company? Update your profile or add contact details — and choose exactly who can reach you. Reviewed before anything is published.